IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.708
+0.026 (3.80%)
At close: Nov 22, 2024, 4:00 PM
0.713
+0.005 (0.65%)
After-hours: Nov 22, 2024, 6:12 PM EST
IO Biotech Employees
IO Biotech had 68 employees as of December 31, 2023. The number of employees increased by 11 or 19.30% compared to the previous year.
Employees
68
Change (1Y)
11
Growth (1Y)
19.30%
Revenue / Employee
n/a
Profits / Employee
-$1,328,529
Market Cap
46.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 68 | 11 | 19.30% |
Dec 31, 2022 | 57 | 25 | 78.13% |
Dec 31, 2021 | 32 | 21 | 190.91% |
Dec 31, 2020 | 11 | - | - |
Related Stocks
Company Name | Employees |
---|---|
SHL Telemedicine | 583 |
Achilles Therapeutics | 215 |
BioLineRx | 79 |
Actinium Pharmaceuticals | 49 |
OncoCyte | 46 |
Envoy Medical | 34 |
SCYNEXIS | 29 |
vTv Therapeutics | 16 |
IOBT News
- 10 days ago - IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 11 days ago - IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - GlobeNewsWire
- 7 weeks ago - IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 2 months ago - IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - GlobeNewsWire
- 3 months ago - IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - GlobeNewsWire
- 3 months ago - IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 4 months ago - IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 - GlobeNewsWire